45 results on '"Gatt, Moshe E."'
Search Results
2. Suppression of multiple myeloma by mitochondrial targeting.
- Author
-
Aisen, Yana, Gatt, Moshe E., Hertz, Rachel, Smeir, Elia, and Bar-Tana, Jacob
- Subjects
- *
MULTIPLE myeloma treatment , *OXIDATIVE stress , *APOPTOSIS , *FATTY acids , *BORTEZOMIB - Abstract
Treatment of multiple myeloma (MM) aims at inducing cell apoptosis by surpassing the limited capacity of MM cells to cope with oxidative stress. MM cell survival may further be suppressed by limiting cellular cholesterol. Long-chain fatty acid analogs of the MEDICA series promote mitochondrial stress and inhibit cholesterol biosynthesis, thus prompting us to verify their efficacy and mode-of-action in suppressing MM cell survival, in comparison to bortezomib. MEDICA analog is shown here to effectively suppress survival of MM cells, and to inhibit growth of MM xenograft. Suppression of MM cell survival by MEDICA is accompanied by inhibition of the STAT3, MAPK and the mTORC1 transduction pathways due to mitochondrial oxidative stress. MEDICA-induced oxidative stress is abrogated by added exogenous cholesterol. Suppression of MM cell survival by bortezomib is similarly driven by bortezomib-induced oxidative stress, being abrogated by added cholesterol. In line with that, the time-to-best-response of MM patients to bortezomib-based treatment protocols is shown to be positively correlated with their plasma cholesterol level. MEDICA profile may indicate novel therapeutic potential in the management of MM. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. Immune Therapies in AL Amyloidosis—A Glimpse to the Future.
- Author
-
Haran, Arnon, Vaxman, Iuliana, Gatt, Moshe E., and Lebel, Eyal
- Subjects
- *
AMYLOIDOSIS treatment , *THERAPEUTIC use of monoclonal antibodies , *SYNDROMES , *NEUROTOXICOLOGY , *IMMUNOGLOBULIN light chains , *IMMUNOTHERAPY , *CYTOKINE release syndrome , *BIOTHERAPY - Abstract
Simple Summary: Light-chain (AL) amyloidosis is a rare disease similar to the more common disease, multiple myeloma (MM). Both are caused by proliferation of malignant plasma cells. In AL amyloidosis, disease is a result of the deposition of aggregates of proteins, namely immunoglobulin light chains, secreted by the malignant plasma cells, in target organs such as the heart or kidneys. Historically, treatment of AL amyloidosis has followed that of MM. A wide range of novel immunotherapies, i.e., therapies which utilize or activate immune mechanisms to eliminate the disease, are already established in MM and are gradually being adopted in AL amyloidosis as well. Although promising, the increased frailty of typical AL amyloidosis compared to MM patients is a concern in the administration of these therapies, which may be associated with severe side effects. We review both the promise and the challenges with the expansion of MM immunotherapies to AL amyloidosis. Light-chain (AL) amyloidosis is a rare plasma cell disorder characterized by the deposition of misfolded immunoglobulin light chains in target organs, leading to multi-organ dysfunction. Treatment approaches have historically mirrored but lagged behind those of multiple myeloma (MM). Recent advancements in MM immunotherapy are gradually being evaluated and adopted in AL amyloidosis. This review explores the current state of immunotherapeutic strategies in AL amyloidosis, including monoclonal antibodies, antibody–drug conjugates, bispecific antibodies, and chimeric antigen receptor T-cell therapy. We discuss the unique challenges and prospects of these therapies in AL amyloidosis, including the exposure of frail AL amyloidosis patients to immune-mediated toxicities such as cytokine release syndrome (CRS) and immune effector-cell-associated neurotoxicity syndrome (ICANS), as well as their efficacy in promoting rapid and deep hematologic responses. Furthermore, we highlight the need for international initiatives and compassionate programs to provide access to these promising therapies and address critical unmet needs in AL amyloidosis management. Finally, we discuss future directions, including optimizing treatment sequencing and mitigating toxicities, to improve outcomes for AL amyloidosis patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Standardization of Molecular MRD Levels in AML Using an Integral Vector Bearing ABL and the Mutation of Interest.
- Author
-
Nachmias, Boaz, Krichevsky, Svetlana, Gatt, Moshe E., Gross Even-Zohar, Noa, Shaulov, Adir, Haran, Arnon, Aumann, Shlomzion, and Vainstein, Vladimir
- Subjects
- *
RESEARCH , *PILOT projects , *GENETICS , *GENETIC mutation , *RETROVIRUSES - Abstract
Simple Summary: Acute Myeloid Leukemia is the most common leukemia in adults and has a dismal prognosis. An allogeneic bone marrow transplant provides the best curative approach. However, due to its related morbidity and mortality, the decision is based on risk assessment at diagnosis and response to therapy. Accurate assessment of molecular Minimal Residual Disease (MRD) has provided a powerful tool to assess the depth of response and risk of relapse. However, validated and standardized molecular MRD is currently limited to typical NPM1 mutations and core-binding factor translocations. To allow for a better standardization of other identified mutations, we constructed a vector that bears both the sequence for the mutation of interest and the ABL1 gene, thus allowing us to calculate the mutation copy number using the inherent ABL1 gene standards. We have implanted this approach in several identified mutations including atypical NPM1, IDH1/2 and RUNX1. Quantitative PCR for specific mutation is being increasingly used in Acute Myeloid Leukemia (AML) to assess Measurable Residual Disease (MRD), allowing for more tailored clinical decisions. To date, standardized molecular MRD is limited to typical NPM1 mutations and core binding factor translocations, with clear prognostic and clinical implications. The monitoring of other identified mutations lacks standardization, limiting its use and incorporation in clinical trials. To overcome this problem, we designed a plasmid bearing both the sequence of the mutation of interest and the ABL reference gene. This allows the use of commercial standards for ABL to determine the MRD response in copy number. We provide technical aspects of this approach as well as our experience with 19 patients with atypical NPM1, RUNX1 and IDH1/2 mutations. In all cases, we demonstrate a correlation between response and copy number. We further demonstrate how copy number monitoring can modulate the clinical management. Taken together, we provide proof of concept of a novel yet simple tool, which allows in-house MRD monitoring for identified mutations, with ABL-based commercial standards. This approach would facilitate large multi-center studies assessing the clinical relevance of selected MRD monitoring. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. The use of serum free light chain dimerization patterns assist in the diagnosis of AL amyloidosis.
- Author
-
Gatt, Moshe E., Kaplan, Batia, Yogev, Dean, Slyusarevsky, Elana, Pogrebijski, Galina, Golderman, Sizilia, Kukuy, Olga, and Livneh, Avi
- Subjects
- *
DIMERIZATION , *PLASMA cell diseases , *AMYLOIDOSIS diagnosis , *WESTERN immunoblotting , *DIFFERENTIAL diagnosis - Abstract
Summary: The discrimination between benign and malignant forms of plasma cell dyscrasia (PCD) is often difficult. Free light chain monomer‐dimer pattern analysis (FLC‐MDPA) may assist in solving this dilemma and distinguish between AL amyloidosis and benign PCD. Serum samples of patients with AL amyloidosis and benign PCD were analysed in a blinded manner. Quantitative Western blotting was performed to estimate dimerization and clonality indices, and thereby determine the source of the tested samples, as derived either from benign or malignant PCD. The findings obtained by the FLC‐MDPA were compared with the actual diagnosis. Of 37 samples from patients with active AL amyloidosis, 34 (91·9%) fulfilled dimerization criteria for diagnosis of AL amyloidosis. Of the 45 samples from patients with benign PCD, 10 (21·2%) tested falsely positive or gave an inconclusive result. Thus, the sensitivity of the analysis was 92·5% with a remarkable negative predictive value of 91·9%. In addition, of 20 patients who were in complete or very good partial remission, only one tested positive. By multivariate analysis, FLC‐MDPA was the best independent marker predicting AL amyloidosis (odds ratio of 84). The FLC‐MDPA offers a highly effective tool in the diagnostic assessment of patients with PCD. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment.
- Author
-
Gatt, Moshe E., Hardan, Izhar, Chubar, Evgeni, Suriu, Celia, Tadmor, Tamar, Shevetz, Olga, Patachenco, Paulina, Dally, Najib, Yeganeh, Shay, Ballan‐Haj, Mouna, Cohen, Yael, Trestman, Svetlana, Muchtar, Eli, Magen, Hila, Jakubinsky, Julia, and Avivi, Irit
- Subjects
- *
AMYLOIDOSIS , *BORTEZOMIB , *ALKYLATION , *ALKYLATING agents , *DRUG administration - Abstract
Light-chain amyloidosis ( AL) is associated with low survival rates, particularly in patients with cardiac involvement. We evaluated the outcome of 73 consecutive, non-selected 'real-world' AL patients, treated with first-line bortezomib-based induction, focusing on the benefit of concurrent administration of alkylating agents. Most patients had renal (77%), cardiac (66%), or multiorgan (74%) involvement. Sixty-eight per cent ( n = 50) received alkylating agent (mostly cyclophosphamide). Severe adverse events were seen in 45%, most evident in patients with cardiac involvement, with no increased toxicity in patients receiving an alkylator agent. Hematological response (HemR) was obtained in 77% of patients, including 33% very good partial responses and 19% complete responses. Age <70 yr, lack of cardiac and peripheral neurologic involvement, and co-administration of an alkylating agent were associated with significantly improved HemR. NYHA cardiac failure staging was the only independent factor affecting overall survival. Administration of an alkylating agent and the achievement of both HemR and organ response were associated with a statistically significant improved survival in those surviving the first 6 months of induction. First-line bortezomib-based regimen resulted in favorable response and survival in newly diagnosed patients. Co-administration of an alkylating agent improved outcome without increasing treatment-related toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
7. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
- Author
-
Muchtar, Eli, Gatt, Moshe E., Rouvio, Ory, Ganzel, Chezi, Chubar, Evgeni, Suriu, Celia, Tadmor, Tamar, Shevetz, Olga, Lavi, Noa, Shochat, Tzippy, Cohen, Yael C., Avivi, Irit, Raanani, Pia, and Magen, Hila
- Subjects
- *
MULTIPLE myeloma treatment , *PROTEASOME inhibitors , *SALVAGE therapy , *CANCER relapse , *BORTEZOMIB , *DRUG resistance in cancer cells , *DRUG efficacy , *THERAPEUTICS , *CANCER treatment - Abstract
Carfilzomib has been established in previous years as a treatment for patients with relapsed and/or refractory multiple myeloma (RR-MM). A retrospective multicentre study to evaluate the clinical use of carfilzomib for RR-MM outside of a clinical trial setting was conducted by our group. One hundred and thirty-five patients were included. All patients had been previously exposed to bortezomib and 93% had also been treated with lenalidomide. The vast majority of patients received carfilzomib as part of a two- or three-drug combination. The overall response rate was 47·2%. Multivariate analysis revealed bortezomib resistance, lenalidomide resistance and albumin <35 g/l to negatively impact the likelihood of achieving response. The median duration of response was 8·4 months, and was significantly higher in patients receiving three-drug combination and patients presenting without extramedullary disease. The median progression-free survival and overall survival for the entire cohort was 4·9 months (95% confidence interval [CI] 3·8-6·4) and 12·2 months (95% CI 9-not reached), respectively. Toxicity was manageable, although treatment-related death was seen in 5% of patients. In the setting of progressive multiple myeloma, carfilzomib in a combination regimens yields effective results with a manageable toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
8. TRIM13 ( RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.
- Author
-
Gatt, Moshe E., Takada, Kohichi, Mani, Mala, Lerner, Mikael, Pick, Marjorie, Hideshima, Teru, Carrasco, Daniel E., Protopopov, Alexei, Ivanova, Elena, Sangfelt, Olle, Grandér, Dan, Barlogie, Bart, Shaughnessy, John D., Anderson, Kenneth C., and Carrasco, Daniel R.
- Subjects
- *
CANCER cell growth , *MULTIPLE myeloma , *NF-kappa B , *PROTEASOMES , *INCURABLE diseases , *CANCER cell proliferation , *BONE marrow - Abstract
Multiple myeloma ( MM) is an incurable neoplasm caused by proliferation of malignant plasma cells in the bone marrow ( BM). MM is characterized frequently by a complete or partial deletion of chromosome 13q14, seen in more than 50% of patients at diagnosis. Within this deleted region the tripartite motif containing 13 ( TRIM13, also termed RFP2) gene product has been proposed to be a tumour suppressor gene ( TSG). Here, we show that low expression levels of TRIM13 in MM are associated with chromosome 13q deletion and poor clinical outcome. We present a functional analysis of TRIM13 using a loss-of-function approach, and demonstrate that TRIM13 downregulation decreases tumour cell survival as well as cell cycle progression and proliferation of MM cells. In addition, we provide evidence for the involvement of TRIM13 downregulation in inhibiting the NF kappa B pathway and the activity of the 20 S proteasome. Although this data does not support a role of TRIM13 as a TSG, it substantiates important roles of TRIM13 in MM tumour survival and proliferation, underscoring its potential role as a novel target for therapeutic intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
9. Light chain amyloidosis 2012: a new era.
- Author
-
Gatt, Moshe E. and Palladini, Giovanni
- Subjects
- *
AMYLOIDOSIS , *ETIOLOGY of diseases , *STEM cell transplantation , *THALIDOMIDE , *DIAGNOSIS , *PROGNOSIS , *THERAPEUTICS - Abstract
AL amyloidosis patients with multi-organ and particularly cardiac involvement have historically been considered to have a bad prognosis. The introduction of autologous stem cell transplantation was associated with unacceptable toxicity in high-risk patients, but responding patients have prolonged overall survival. Toxicities can be decreased by careful patient selection, but this reduces the applicability of this treatment modality to a limited number of patients. Efforts are therefore needed to design novel more effective regimens, with the use of new medications, such as thalidomide, lenalidomide and bortezomib, next generation immunomodulatory drugs and proteasome inhibitors. Their combination with dexamethasone and alkylating agents show promising results, allowing a high percentage of remission and subsequent event-free and overall survival, even in a significant proportion of high risk, poor prognosis populations. This review includes the state-of-the-art treatment for AL amyloidosis patients as of 2012, in light of the progress in management of this disease during recent years. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
10. High incidence of skin rash in patients with hairy cell leukemia treated with cladribine.
- Author
-
Ganzel, Chezi, Gatt, Moshe E., Maly, Alexander, Ben-Yehuda, Dina, and Goldschmidt, Neta
- Subjects
- *
DISEASE incidence , *LYMPHOPENIA , *HAIRY cell leukemia , *IMMUNOSUPPRESSION , *CO-trimoxazole - Abstract
Treatment of hairy cell leukemia (HCL) with cladribine induces durable remissions. Common toxicities are myelosuppression and immunosuppression with low counts of CD4 + T cells. Skin rash (SR) is seldom described. We collected clinical and laboratory data of 35 patients with HCL treated in Hadassah between January 1999 and February 2010, in order to evaluate the frequency and characteristics of SR after treatment with cladribine. We found a high frequency of SR in our group of patients (18/35 patients, 51%), mostly related to febrile neutropenia and concomitant treatment with penicillins/trimethoprim-sulfamethoxazole (TMP-SMZ). The lymphocyte count was low in all patients with SR. We conclude that patients with HCL treated with cladribine have an increased rate of drug hypersensitivity, possibly due to T-cell imbalance induced by cladribine. Since TMP-SMZ and penicillins are related to SR in most cases and are important in the management of patients with HCL, a desensitization protocol should be considered. Rechallenge may be safe after immune reconstitution. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
11. Chronic Lymphocytic Leukemia Presenting with Extreme Hyperleukocytosis and Thrombosis of the Common Femoral Vein.
- Author
-
Cukierman, Tali, Gatt, Moshe E., Libster, Dianna, Goldschmidt, Neta, and Matzner, Yaacov
- Subjects
- *
CHRONIC lymphocytic leukemia , *VENOUS thrombosis , *COMORBIDITY - Abstract
Very few case reports dealing with chronic lymphocytic leukemia (CLL) and hypefieukocytosis have been reported in the medical literature and none with venous thrombosis as a complication. Here, we describe a 73-year-old woman who presented with newly diagnosed CLL, leukostasis, and hyperleukocytosis (2000 × 10[sup 9]/l), affecting the respiratory and nervous system. In addition, she also had deep vein thrombosis (DVT). Although hypercoagulability and thrombosis are well-described phenomena in solid tumors and in myeloproliferative neoplasms, CLL is generally not associated with an acquired coagulopathy. We hypothesize that in our patient the extreme number of circulating lymphocytes resulted in an abnormal accumulation of lymphocytes possibly causing stasis and occlusion of a larger vessel, which resolved after leukopheresis. The patient has since been successfully maintained with chemotherapy. We conclude that leukopheresis should be considered as the therapy of choice in CLL patients presenting with major complications of leukostasis. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
12. Characteristics and outcome of multiple myeloma patients presenting with anaemia only: A retrospective multi-centre study.
- Author
-
Shragai, Tamir, Gatt, Moshe E., Shaulov, Adir, Katodritou, Eirini, Triantafyllou, Theodora, Lavi, Noa, Pouli, Anastasia, Sioni, Anastasia, Vaxman, Iuliana, Zektser, Miri, Ganzel, Chezi, Benyamini, Noam, Trestman, Svetlana, Ziv-Baran, Tomer, Adam, Yasmin, Cohen, Yael C., and Avivi, Irit
- Subjects
- *
MULTIPLE myeloma , *ANEMIA , *PLASMACYTOMA , *BONE marrow , *PLASMA cells , *RETROSPECTIVE studies - Abstract
• Patients with Multiple myeloma presetting with anaemia only are rare. • Anaemia-only MM patients have higher degree of bone marrow plasmacytosis. • Anaemia-only MM patients showed lower rates of deep responses to induction therapy. • Anaemia-only MM patients represents a unique, potentially less favorable population. Multiple myeloma (MM) patients presenting with anaemia as their sole clinical manifestation are rare and not fully defined. Retrospective multi-site study comparing the characteristics and outcome of MM patients with anaemia only with matched patients, presenting with multi-organ disease. Anaemia-only patients had a higher percentage of bone marrow monoclonal plasma cells group (median 60% [IQR 42−80%] vs. 37% [IQR 17–65%], respectively; p < 0.001), and a lower responsiveness to treatment (≥VGPR rates were 54% vs 74%, p = 0.049). Median survival in anaemia only patients was 65.9 ± 6.9 vs 83.4 ± 8.8 months in matched control patients (P = n.s). MM patients presenting with anaemia only represents a unique, potentially less favorable population. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. The impact of anti-bacterial prophylaxis on the outcome of patients treated with venetoclax-based regimens for relapsed/refractory plasma cell dyscrasias: Real-life data.
- Author
-
Avivi, Irit, Gatt, Moshe E., Luttwak, Efrat, Magen, Hila, Dally, Najib, Cohen, Yael C., Benyamini, Noam, and Lavi, Noa
- Subjects
- *
PLASMA cell diseases , *PNEUMOCYSTIS pneumonia , *PNEUMOCYSTIS jiroveci , *PREVENTIVE medicine , *INSTITUTIONAL review boards - Published
- 2020
- Full Text
- View/download PDF
14. A Bortezomib-Based Protocol Induces a High Rate of Complete Remission with Minor Toxicity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
- Author
-
Nachmias, Boaz, Shaulov, Adir, Gatt, Moshe E., Shapira, Michael, and Gural, Alexander
- Subjects
- *
BORTEZOMIB , *BONE marrow transplantation , *CANCER chemotherapy , *HEMATOLOGIC malignancies , *GRAFT versus host disease - Abstract
The treatment of relapsed/refractory acute lymphoblastic leukemia (RR-ALL) presents a true clinical challenge. In 2012, a protocol combining bortezomib, dexamethasone, asparaginase, doxorubicin, and vincristine administered to children with RR-ALL was published with encouraging results. Over the past 5 years, we have implemented this protocol in the adult RR-ALL population (> 18 years) and addressed its feasibility in terms of remission rate and toxicity. Here, we present the results of our experience in 9 patients, all of whom received multiple previous chemotherapy protocols, two of them relapsing after an allogeneic bone marrow transplantation. All of the five B-ALL patients, and two of the four T-ALL achieved complete remission. Of the seven patients achieving complete remission, two patients were referred for allogeneic bone marrow transplantation, two patients were subsequently given blinatumomab, and one patient subsequently received donor lymphocyte infusion followed by blinatumomab. Thus, five out of nine patients treated (55%) were able to proceed to best available therapy in a complete remission. We observed minimal adverse effects, mainly hematological toxicity. We conclude that the bortezomib-based protocol should be evaluated as an effective and well-tolerated treatment option for adult patients either unfit for or failing standard salvage chemotherapy, as a bridge to immunotherapy or allogeneic bone marrow transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
15. Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?
- Author
-
Vainstein, Vladimir, Avni, Batia, Grisariu, Sigal, Kfir-Erenfeld, Shlomit, Asherie, Nathalie, Nachmias, Boaz, Auman, Shlomtzion, Saban, Revital, Zimran, Eran, Assayag, Miri, Filanovsky, Kalman, Horowitz, Netanel A., Lebel, Eyal, Shaulov, Adir, Gur, Michal, Rosenbluh, Chaggai, Krichevsky, Svetlana, Stepensky, Polina, and Gatt, Moshe E.
- Subjects
- *
MYELODYSPLASTIC syndromes , *GENETIC mutation , *CELL receptors , *RETROSPECTIVE studies , *ATTRIBUTION (Social psychology) , *MULTIPLE myeloma , *HEMATOPOIESIS , *POLYMERASE chain reaction ,BONE marrow examination - Abstract
Simple Summary: Patients suffering from multiple myeloma receive many lines of treatment including chimeric antigen receptor T cell (CART) therapy. Myeloma patients may develop devastating secondary malignancies such as myelodysplastic syndrome (MDS). The causative relationship between various anti-myeloma treatments and MDS is not fully understood. We report a study of five CART-treated patients myeloma patients who had MDS (four only after CART and one already prior to CART). We found that all these patients had all their MDS-related molecular changes (mutations) already prior to CART even if they did not have overt MDS in bone marrow evaluation before CART. No new mutations developed after CART, but the frequency of pre-existing mutations did increase. Our study presents evidence that anti-myeloma CART therapy may promote the expansion of pre-existing MDS clones rather than causing the development of new ones. Multiple myeloma (MM) is characterized by recurrent relapses. Consequently, patients receive multiple therapy lines, including alkylating agents and immune modulators, which have been associated with secondary malignancies such as myelodysplastic syndrome (MDS). Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T cell (CART) therapy is efficacious in patients with relapsed/refractory (R/R) MM. However, the long-term complications, particularly MDS, are not well understood. Whether CART therapy causes or promotes MDS has not been thoroughly investigated. In this study, we explored the causal relationship between MDS and CART therapy. We retrospectively examined the prevalence of MDS-related morphological and mutational changes before and after administration of CART therapy in five patients. Among them, four developed MDS after CART therapy, while one had pre-existing MDS prior to CART. None of the four patients who developed post-CART MDS showed morphological MDS changes prior to CART therapy. However, all four patients exhibited molecular alterations associated with MDS in their pre-CART as well as post-CART therapy bone marrow. No new mutations were observed. Our findings provide initial evidence suggesting that anti-BCMA CART therapy in MM may promote expansion of pre-existing MDS clones rather than causing development of new clones. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity‐induced rash in patients with multiple myeloma.
- Author
-
Shamriz, Oded, Parnasa, Elchanan, Rubin, Limor, Talmon, Aviv, Ribak, Yaarit, Lebel, Eyal, Vainstein, Vladimir, Aumann, Shlomzion, Saban, Revital, Gatt, Moshe E., and Tal, Yuval
- Subjects
- *
MEDICAL protocols , *LENALIDOMIDE , *ALLERGY desensitization , *MULTIPLE myeloma , *TREATMENT delay (Medicine) , *DELAYED hypersensitivity - Abstract
Introduction and Objectives: Lenalidomide is considered a standard of care in multiple myeloma (MM) Some MM patients will develop delayed hypersensitivity to lenalidomide, which can lead to treatment discontinuation. Desensitization to lenalidomide can help these patients to complete treatment courses. Here, we aimed to review lenalidomide‐treated MM patients who developed delayed hypersensitivity‐induced rash and were treated with desensitization. Methods: A retrospective analysis of medical files of MM patients, who were desensitized to lenalidomide due to delayed hypersensitivity rash. Patients were treated between 2018 and 2022 at Hadassah Medical Center, Jerusalem, Israel. Results: Search of patients yielded 16 patients that underwent desensitization to lenalidomide within the study period. The desensitization protocol consisted of a slow, 3‐week‐long protocol with lenalidomide's target doses of 10, 15, and 25 mg/day. Of the 16 patients, 10 (62.5%) succeeded to complete the protocol and thus were able to complete lenalidomide treatment cycles. One patient with unsuccessful desensitization was subsequently treated with first‐generation IMiD thalidomide, with no rash appearing. None of the patients that were treated with desensitization had severe immune‐mediated or non‐dermatological adverse reactions. Conclusions: Desensitization to lenalidomide is safe and effective. Discontinuation of lenalidomide in MM patients with delayed hypersensitivity and no contraindication to desensitization should be discouraged. Collaboration between hematologists and allergists is needed. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Venetoclax in Relapse/Refractory AL Amyloidosis—A Multicenter International Retrospective Real-World Study.
- Author
-
Lebel, Eyal, Kastritis, Efstathios, Palladini, Giovanni, Milani, Paolo, Theodorakakou, Foteini, Aumann, Shlomzion, Lavi, Noa, Shargian, Liat, Magen, Hila, Cohen, Yael, Gatt, Moshe E., and Vaxman, Iuliana
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *RESEARCH , *AMYLOIDOSIS , *INTERNATIONAL relations , *CONFIDENCE intervals , *CHRONIC diseases , *CANCER relapse , *RETROSPECTIVE studies , *TREATMENT effectiveness , *TUMOR lysis syndrome , *DISEASE prevalence , *DESCRIPTIVE statistics , *LYMPHOPROLIFERATIVE disorders , *MEDICAL prescriptions , *PROGRESSION-free survival , *LONGITUDINAL method , *DRUG resistance in cancer cells , *OVERALL survival - Abstract
Simple Summary: Light-chain amyloidosis is a rare disease, and treatment for relapsed light-chain amyloidosis patients is an unmet need. Venetoclax is an oral medication that has proven great efficacy in many hematological cancers, including multiple myeloma. Venetoclax is considered a promising agent for the treatment of relapsed light-chain amyloidosis. We aimed to report the outcomes of therapy in 26 relapsed light-chain amyloidosis patients treated with venetoclax. We found a very high response rate (88%), and most responses were deep and prolonged. Treatment was effective even when doses were reduced. Venetoclax treatment was safe, and one patient died due to infection. These promising results require confirmation in a randomized trial. Therapeutic options in relapsed refractory (R/R) light-chain (AL) amyloidosis patients are limited. Given the encouraging results in t(11;14) multiple myeloma and the high prevalence of t(11;14) in AL amyloidosis, venetoclax is an attractive treatment option in this setting. We report here the results of a multi-center retrospective study on 26 R/R AL amyloidosis patients treated off-label with venetoclax. The median lines of therapy prior to venetoclax was 3.5 (range 1–7), and 88% of our cohort had t (11;14). Twenty-two patients (85%) were previously treated with daratumumab. The overall hematologic response rate was 88%, 35% achieved a CR, and 35% achieved VGPR. The median event-free survival was 25 months (m) (95% CI 9.7 m-not reached), and the median overall survival was 33 m (95% CI 25.9–39.2 m). Most of the patients in this cohort are in ongoing deep responses and continuing venetoclax therapy. The treatment was relatively safe. One patient died due to infection, and there were two grade 3 infections in our cohort. Tumor lysis syndrome (TLS) was not seen in any patient. Dose reductions were frequent but did not affect the efficacy. These promising results require confirmation in a randomized controlled trial. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group.
- Author
-
Ganzel, Chezi, Trestman, Svetlana, Levi, Shai, Gatt, Moshe E., Lavi, Noa, Vaxman, Iuliana, Rouvio, Ory, Magen, Hila, Lebel, Eyal, Horowitz, Netanel A., Leiba, Merav, Tadmor, Tamar, Herzog Tzarfati, Katrin, Surio, Celia, Yeganeh, Shay, Dally, Nagib, Avivi, Irit, and Cohen, Yael C.
- Subjects
- *
PLASMACYTOMA , *PROGNOSIS , *IMMUNOGLOBULIN light chains , *EXTRAMEDULLARY diseases , *MULTIPLE myeloma , *PLASMA cells - Abstract
Solitary plasmacytoma (SP) is a rare plasma cell dyscrasia. In this retrospective multicenter study, 68 SP patients were included. Compared to solitary extramedullary plasmacytoma (SEP), patients with solitary bone plasmacytoma (SBP) were younger (57.3 vs. 70.9 years, p = 0.031), had larger plasmacytoma (median: 5.4 vs. 3 cm, p = 0.007) and higher median involved free light chain level (61 vs. 25.8 mg/L, p = 0.056). 92.6% of patients were treated by radiotherapy and 11.8% received systemic anti-myeloma treatment. With a median follow-up of 42 months, 45.6% of patients progressed (8.8% – recurrent SP, 36.8% – active myeloma). The median PFS was 58 months and the median OS has not been reached (10-year OS: 84.8%). Patients who received also anti-myeloma treatment had longer PFS compared to those who did not (median not reached vs. 48 months, p = 0.056). In conclusion, SBP and SEP appear to be different diseases. Radiotherapy is the cornerstone in the SP treatment. A large prospective trial is needed to evaluate the impact of adding systemic anti-myeloma treatment to local radiotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia.
- Author
-
Nachmias, Boaz, Krichevsky, Svetlana, Filon, Dvora, Even-Or, Ehud, Gatt, Moshe E., Saban, Revital, Avni, Batia, Grisariu, Sigal, Aumann, Shlomzion, and Vainstein, Vladimir
- Subjects
- *
ACUTE myeloid leukemia , *INDIVIDUALIZED medicine , *PROGNOSIS , *FLOW cytometry - Abstract
Introduction: Mutated RUNX1 is considered a poor prognostic factor and usually is mutually exclusive with NPM1 mutations. Monitoring of molecular markers for minimal residual disease provides a powerful tool to assess remission and guide clinical decisions. Methods: Newly diagnosed RUNX1-mutated AML patients, designated to intensive chemotherapy-based treatment or nonintensive regimens, were monitored for mutated RUNX1 transcript levels by qPCR with patient-specific primers. Samples were obtained along the treatment course and follow-up. Results: A clear correlation was observed between mutated RUNX1 levels and response to treatment as observed by flow cytometry and STR-based assessment. Conclusion: We demonstrate the feasibility of RUNX1-based MRD to correlate with the clinicopathological status of leukemia. We further suggest how RUNX1 qPCR monitoring can influence clinical decision-making and contribute to improved personalized patient care. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. A Fractured Diagnosis.
- Author
-
Cukierman, Tali, Gatt, Moshe E., Hiller, Nurith, and Chajek-Shaul, Tova
- Subjects
- *
OLDER women , *HOSPITAL emergency services , *OSTEOMALACIA , *WEIGHT loss , *BONE diseases , *VITAMIN D deficiency , *BONE fractures , *BONE injuries - Abstract
Presents the case of a 44-year-old woman who was admitted to the emergency department because of pain in her right thigh shortly after a minor fall. Description of her symptoms and past medical history; Recent weight loss of the patient; Speculation on her diagnosis; Assertion that the examination of the patient revealed a low bone density characteristic of osteomalacia; Treatment of the patient and her recovery.
- Published
- 2005
- Full Text
- View/download PDF
21. My lousy doctor.
- Author
-
Gatt, Moshe E
- Subjects
- *
PHYSICIANS , *SYMPTOMS , *FEVER , *ABDOMEN - Abstract
Presents the author's experiencing in trying to diagnose his own ailment. Symptoms experienced including fever and tenderness in the abdomen; How the author is a physician; Decision to be admitted to the hospital and subsequent treatment.
- Published
- 2004
- Full Text
- View/download PDF
22. Treatment of Tobacco Use and Dependence.
- Author
-
Gatt, Moshe E. and Heyman, Samuel N.
- Subjects
- *
LETTERS to the editor , *TOBACCO - Abstract
A letter to the editor is presented in response to an article on tobacco use in the February 14, 2002 issue.
- Published
- 2002
- Full Text
- View/download PDF
23. Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphoma.
- Author
-
Lebel, Eyal, Goldschmidt, Neta, Siegal, Tali, Lossos, Alexander, Rosenberg, Shai, Makranz, Chen, Linetski, Eduard, Gatt, Moshe E., Gural, Alexander, Saban, Revital, Lavie, David, Vainstein, Vladimir, Zimran, Eran, Avni, Batia, Grisaro, Sigal, Shaulov, Adir, and Nachmias, Boaz
- Subjects
- *
CENTRAL nervous system , *METHOTREXATE , *RITUXIMAB , *HEALTH facilities , *AUTOGRAFTS - Abstract
The optimal high-dose methotrexate (HDMTX)-based combination therapy for primary central nervous system lymphoma is unknown. We report our experience with rituximab, HDMTX, procarbazine and lomustine (R-MPL) given as first-line treatment in our center. Fifty-two patients between 2006 and 2019 were included. Eighteen patients proceeded to autologous transplant or two cycles of intermediate-dose cytarabine. The median age was 62 y (range 28–94) and the Eastern Cooperative Oncology Group performance status (ECOG-PS) was ≥2 in 62% (32/52). The overall/complete response rates were 79% (41/52) and 52% (27/52), respectively. The median progression-free/overall survival was 19 m/84m, respectively. Grade 3–4 adverse events included infections (17%) and kidney injury (13%). Ten patients (19%) discontinued therapy for toxicity. There were no treatment-related deaths. In summary, in a cohort enriched in frail patients, R-MPL achieved good responses and OS and was safe for all ages. The PFS was sub-optimal, possibly explained by a low proportion of consolidation. This regimen should be evaluated prospectively. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival.
- Author
-
Gross Even-Zohar, Noa, Pick, Marjorie, Hofstetter, Liron, Shaulov, Adir, Nachmias, Boaz, Lebel, Eyal, and Gatt, Moshe E.
- Abstract
Surface antigens are commonly used in flow cytometry assays for the diagnosis of multiple myeloma (MM). Some of these are directly involved in MM pathogenesis or interactions with the microenvironment, but most are used for either diagnostic or prognostic purposes. In a previous study, we showed that in-vitro, CD24-positive plasma cells exhibit a less tumorigenic phenotype. Here, we assessed the prognostic importance of CD24 expression in patients newly diagnosed with MM as it correlates to their clinical course. Immunophenotyping by flow cytometry of 124 patients uniformly treated by a bortezomib-based protocol was performed. The expression of CD24, CD117, CD19, CD45, and CD56 in bone marrow PCs was tested for correlations to clinical parameters. None of the CD markers correlated with the response rates to first-line therapy. However, patients with elevated CD24+ expression on their PCs at diagnosis had a significantly longer PFS (p = 0.002) and OS (p = 0.044). In contrast, the expression of CD117, CD56, or CD45 was found to have no prognostic value; CD19 expression was inversely correlated with PFS alone (p < 0.001) and not with OS. Thus, elevated CD24 expression on PCs appears to be strongly correlated with survival and can be used as a single-surface antigenic prognostic factor in MM. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma.
- Author
-
Lebel, Eyal, Nachmias, Boaz, Pick, Marjorie, Gross Even-Zohar, Noa, and Gatt, Moshe E.
- Subjects
- *
CELL surface antigens , *MULTIPLE myeloma , *PROGNOSIS , *MESENCHYMAL stem cells , *PLASMA cells - Abstract
Multiple myeloma (MM) progression is dependent on its interaction with the bone marrow microenvironment and the immune system and is mediated by key surface antigens. Some antigens promote adhesion to the bone marrow matrix and stromal cells, while others are involved in intercellular interactions that result in differentiation of B-cells to plasma cells (PC). These interactions are also involved in malignant transformation of the normal PC to MM PC as well as disease progression. Here, we review selected surface antigens that are commonly used in the flow cytometry analysis of MM for identification of plasma cells (PC) and the discrimination between normal and malignant PC as well as prognostication. These include the markers: CD38, CD138, CD45, CD19, CD117, CD56, CD81, CD27, and CD28. Furthermore, we will discuss the novel marker CD24 and its involvement in MM. The bioactivity of each antigen is reviewed, as well as its expression on normal vs. malignant PC, prognostic implications, and therapeutic utility. Understanding the role of these specific surface antigens, as well as complex co-expressions of combinations of antigens, may allow for a more personalized prognostic monitoring and treatment of MM patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. Dose-adjusted EPOCH-R is not superior to sequential R-CHOP/R-ICE as a frontline treatment for newly diagnosed primary mediastinal B-cell lymphoma: Results of a bi-center retrospective study.
- Author
-
Morgenstern, Yael, Aumann, Shlomzion, Goldschmidt, Neta, Gatt, Moshe E., Nachmias, Boaz, and Horowitz, Netanel A.
- Subjects
- *
FEBRILE neutropenia , *DIFFUSE large B-cell lymphomas , *ELECTRONIC health records , *LYMPHOMAS - Abstract
Purpose: Primary mediastinal B-cell lymphoma (PMBCL) is a rare subtype of diffuse large B-cell lymphoma (DLBCL). Despite its aggressive course, PMBCL is considered curable. While in recent years dose-adjusted (DA) EPOCH-R (rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin) has become widely endorsed as first-line therapy for newly-diagnosed PMBCL, the optimal treatment for this disease and the role of radiotherapy (RT) remains unclear. DA-EPOCH-R provides good clinical outcomes, albeit is associated with short-and long-term toxicity. To address this issue, the current retrospective bi-icenter analysis compared efficacy and toxicity of DA-EPOCH-R and a less toxic R-CHOP/R-ICE regimen used for the treatment of newly-diagnosed PMBCL. Patients and Methods: The study included all patients with a histologically confirmed PMBCL diagnosis treated with DA-EPOCH-R or R-CHOP/R-ICE between 01/2013-12/2020 at two tertiary medical centers. Patient demographic and clinical data were derived from institutional electronic medical records. The analysis included 56 patients: 31 received DA-EPOCH-R and 25 -R- CHOP/R-ICE. Results: At a median follow-up of 1.9 years (IQR 3.1 years), similar progression-free survival (2.1 versus 2.4 years; p = 0.7667), overall survival (2.5 versus 2.7 years; p = 0.8047) and complete response (80%) were observed in both groups. However, DA-EPOCH-R was associated with significantly longer hospitalization required for its administration (p < 0.001) and a trend for higher frequency of infections, stomatitis, thrombotic complications and febrile neutropenia-related hospitalizations. Conclusion: DA-EPOCH-R and R-CHOP/R-ICE provide similarly encouraging outcomes in newly-diagnosed PMBCL patients. R-CHOP/R-ICE is associated with lower toxicity and significantly reduced hospitalization. Our findings suggest that this regimen may be considered as an alternative to DA-EPOCH-R in this patient population. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
27. Prolonged ileus as a sole manifestation of pseudomembranous enterocolitis.
- Author
-
Elinav, Eran, Planer, David, and Gatt, Moshe E.
- Subjects
- *
ENTERITIS , *INTESTINAL diseases , *CLOSTRIDIOIDES difficile , *BOWEL obstructions , *PATIENTS - Abstract
Background. Pseudomembranous colitis usually manifests as fever and diarrhea in hospitalized patients treated with systemic antibiotics. We present a case that represents a unique variant. Case presentation. The 44-year-old man suffered of several weeks of abdominal pain, low-grade fever, nausea, vomiting, and lack of bowel movements. Upper gastrointestinal barium swallow and passage series revealed evidence of severe intestinal hypomotility. A thorough evaluation for the cause of the patient’s ileus and abdominal pain was unrevealing, and symptomatic treatment was ineffective. Following the administration of opiates and dietary fiber supplementation the patient’s abdominal pain and distention rapidly worsened, requiring an urgent subtotal colectomy. The macroscopic and microscopic appearance of the excised colon as well as results of the colonic cytotoxin essay and fecal enzyme-linked immunosorbent assay essay confirmed the diagnosis of severe Clostridium difficile induced pseudomembranous colitis as the cause of the patient’s illness. Conclusion. To our knowledge, this is the first reported case of Clostridium-difficile induced disease consisting of prolonged ileus in the absence of diarrhea in a patient not previously taking antibiotics. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
28. Serum Hevylite® assay in the differential diagnosis of patients with high suspicion of AL Amyloidosis.
- Author
-
Yogev, Dean, Pick, Marjorie, Slyusarevsky, Elena, Pogrebijski, Galina, Pickin, Anna, and Gatt, Moshe E.
- Subjects
- *
AMYLOIDOSIS diagnosis , *BIOMARKERS , *AMYLOIDOSIS , *IMMUNOGLOBULINS , *CONFIDENCE intervals , *MULTIVARIATE analysis , *DIFFERENTIAL diagnosis , *DESCRIPTIVE statistics , *BIOLOGICAL assay , *ODDS ratio , *LONGITUDINAL method , *SYMPTOMS - Abstract
Introduction: AL amyloidosis (AL) is a malignant form of plasma cell dyscrasia (PCD). It is insidious, and its end‐organ damage can mimic that of common diseases. At diagnosis, routine tests for monoclonal protein are insufficient for the differential diagnosis. We hypothesized that Hevylite® (HLC) isotype patterns may help discriminate between AL and benign PCD states. Methods: Serum samples of patients with a high clinical suspicion of AL were prospectively tested for IgGκ, IgGλ, IgAκ, IgAλ, IgMκ, and IgMλ concentrations and ratios using Hevylite® assays in a blinded manner. The results were correlated with the final diagnosis. Results: Of the 99 samples analyzed, 46 were newly diagnosed AL, and the majority, 38 (82.6%), presented with suppression of at least one HLC isotype. Of the 53 benign PCD patients, 36 (67.9%) presented with elevation of at least one HLC isotype. By multivariate analysis, Hevylite® was the best independent test predictor of AL amyloidosis. HLC suppression had an odds ratio (OR) of 14.591, and elevation an OR of 10.149, and thus were significant variables in the diagnosis and exclusion of AL. Furthermore, patients with both HLC suppression, together with no elevation, had an OR of 316.69 to be diagnosed with AL rather than a benign PCD. Conclusions: Hevylite® HLC analysis for Ig isotypes patterns offers an effective non‐invasive tool in the evaluation of patients with high suspicion of AL and may assist further explorative decisions for diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
29. Neurological misdiagnoses of lymphoma.
- Author
-
Makranz, Chen, Arkadir, David, Nachmias, Boaz, Gatt, Moshe E., Eliahou, Ruth, Atlan, Karine, Mordechai, Anat, Goldshmit, Netta, and Lossos, Alexander
- Subjects
- *
MYELIN sheath diseases , *PERIPHERAL nervous system , *LYMPHOMAS , *CENTRAL nervous system , *NERVOUS system ,BONE marrow examination - Abstract
Background: Lymphoma of the nervous system is rare and usually involves the brain, spinal cord, or peripheral nerves. Hence, it has varied clinical presentations, and correct diagnosis is often challenging. Incorrect diagnosis delays the appropriate treatment and affects prognosis. We report 5 patients with delayed diagnosis of lymphoma involving the central and/or peripheral nervous system, initially evaluated for other neurological diagnoses. We also discuss the challenge of diagnosis and appropriate testing. Methods: Retrospective review of 2011–2019 records of patients with confirmed nervous system lymphoma diagnosed in a tertiary care medical center. Results: We present 5 adult patients initially evaluated for inflammatory myelopathy, inflammatory lumbosacral plexopathy, atypical parkinsonism, and demyelinating disease of the CNS. Final diagnosis of the nervous system lymphoma was delayed by 4 to 18 months and was based on tissue biopsy in 4, and on CSF and bone marrow examination in 1 patient. Conclusions: Lymphoma may imitate various central and peripheral nervous system disorders. We suggest several red flags that indicate the need to consider lymphoma, including subacute but progressive symptomatic evolution, painful neurological deficit, unclear clinical diagnosis, and transient steroid responsiveness. Correct diagnosis often requires a combination of diagnostic tests, while pathology testing is crucial for early diagnosis and is strongly recommended in the appropriate clinical setting. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
30. Venous Thromboembolism Prophylaxis with Low-Molecular-Weight Heparin in Primary Central Nervous System Lymphoma.
- Author
-
Gazal, Stav, Lebel, Eyal, Kalish, Yosef, Makranz, Chen, Gatt, Moshe E., Goldschmidt, Neta, and Nachmias, Boaz
- Subjects
- *
THROMBOEMBOLISM , *CENTRAL nervous system , *DIFFUSE large B-cell lymphomas , *LOW-molecular-weight heparin , *DRUG efficacy , *LYMPHOMAS - Abstract
Background: Venous thromboembolism (VTE) is a frequent, potentially lethal complication in individuals with cancer. Patients with brain tumors are at particularly high risk for VTE. Primary central nervous system lymphoma (PCNSL) is a rare subtype of diffuse large B cell lymphoma, involving the craniospinal axis. The incidence of VTE in patients with PCNSL was reported as very high, occurring mostly in the early period of therapy. Objectives: We aimed to evaluate the efficacy and safety of prophylactic low-molecular-weight heparin (LMWH) throughout the treatment of PCNSL. Patients: All patients >18 years of age diagnosed and treated for PCNSL at our institution in 2005–2017 were included. Results: There were 44 patients; mean age at diagnosis was 61.5 years. Three patients (6.8%) had a personal history of thrombosis, 11 (25%) had a history of diabetes or smoking, and 32 (72%) had an Eastern Cooperative Oncology Group performance status of 0–1 at diagnosis. During treatment with LMWH, no VTE events were recorded; 2 (4.5%) patients experienced a minor bleeding event and 1 (2.3%) a major bleeding event. Conclusions: Among our 44 patients with PCNSL treated with prophylactic LMWH, no VTE events were recorded, and only 1 (asymptomatic) intracranial bleed was recorded. Within the limitations of a retrospective nonrandomized study, our findings suggest that VTE prophylaxis may be beneficial for individuals with PCNSL. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
31. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
- Author
-
Cohen, Yael C., Magen, Hila, Lavi, Noa, Gatt, Moshe E., Chubar, Evgeni, Horowitz, Nethanel, Kreiniz, Natalia, Tadmor, Tamar, Trestman, Svetlana, Vitkon, Roy, Rouvio, Ory, Shvetz, Olga, Shaulov, Adir, Ziv-Baran, Tomer, and Avivi, Irit
- Subjects
- *
MULTIPLE myeloma , *CLINICAL trials , *PROTEASOME inhibitors , *PROGRESSION-free survival , *BORTEZOMIB , *MONOCLONAL gammopathies , *MULTIPLE myeloma diagnosis , *RESEARCH , *GLYCINE , *BORON compounds , *RESEARCH methodology , *ANTINEOPLASTIC agents , *ACQUISITION of data , *EVALUATION research , *MEDICAL cooperation , *RANDOMIZED controlled trials , *DISEASE relapse , *TREATMENT effectiveness , *COMPARATIVE studies , *LONGITUDINAL method - Abstract
Ixazomib, the first oral proteasome inhibitor (PI), has been approved for the treatment of relapsed refractory multiple myeloma (RRMM) in combination with lenalidomide and dexamethasone, based on the TOURMALINE-MM1 phase 3 trial, which demonstrated the efficacy and safety of this all-oral triplet, compared with lenalidomide-dexamethasone. However, clinical trial outcomes do not always translate into real-world outcomes. The aim of this study was to assess the outcomes of ixazomib-based combination for treatment of patients with RRMM in a real-world setting. All consecutive RRMM patients who received at least one cycle of ixazomib-based treatment combination between June 2013 and June 2018 were identified. Data was extracted from medical charts focusing on demographics, disease characteristics, prior treatment, and responses. Primary endpoint was progression-free survival (PFS); secondary endpoints included overall response rate (ORR), overall survival (OS), safety, and tolerability. A total of 78 patients across 7 sites were retrospectively included. Median follow-up was 22 months. Median age was 68 (range 38-90). Sixty-four percent received ixazomib in 2nd line, 19% in 3rd line. Overall, 89% of patients had been exposed to PIs (bortezomib 87%) prior to IRd, 41% to IMiDs. Twenty-nine (48%, of 60 available) had high (t(4:14), t(14:16), del17p) or intermediate (+1q21) risk aberrations. Most patients (82%) received ixazomib in combination with lenalidomide and dexamethasone. An exploratory assessment for disease aggressiveness at diagnosis was classified by a treating physician as indolent (rapid control to protect from target organ damage not required) vs aggressive (imminent target organ damage) in 63% vs 37%, respectively. Treatment was well tolerated, with a low discontinuation rate (11%). Median PFS on ixazomib therapy was 24 months (95% CI 17-30). PFS was 77% and 47% at 12 and 24 months, respectively. Median OS was not reached; OS was 91% and 80% at 12 and 24 months, respectively. Higher LDH, older age, and worse clinical aggressiveness were associated with worse PFS, whereas a deeper response to ixazomib (≥ VGPR) and a longer response to first-line bortezomib (≥ 24 m) were associated with an improved PFS on ixazomib. No effect on PFS was found for cytogenetic risk by FISH, ISS/rISS, and prior anti-myeloma treatment. Ixazomib-based combinations are efficacious and safe regimens in RRMM patients in the real-world setting, regardless to cytogenetic risk, with a PFS of 24 months comparable with clinical trial data. This regimen had most favorable outcomes among patients who remained progression-free more than 24 months after a bortezomib induction and for those who have a more indolent disease phenotype. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
32. Evaluation of cerebrospinal clonal gene rearrangement in newly diagnosed non-Hodgkin's lymphoma patients.
- Author
-
Nachmias, Boaz, Sandler, Veronica, Slyusarevsky, Elena, Pogrebijski, Galina, Kritchevsky, Svetlana, Ben-Yehuda, Dina, Goldschmidt, Neta, and Gatt, Moshe E.
- Subjects
- *
LYMPHOMAS , *GENE rearrangement , *CENTRAL nervous system , *REARRANGEMENTS (Chemistry) , *CEREBROSPINAL fluid - Abstract
Overt central nervous system (CNS) involvement in aggressive non-Hodgkin's lymphoma (NHL) is rare at diagnosis. Much effort is put to identify risk factors for occult CNS involvement, and the risk assessment of CNS relapse. Prophylactic treatment carries risk of adverse events and its efficacy is not clear. Detection of cerebrospinal fluid molecular gene rearrangement (GRR) as a method to detect occult disease has been studied in acute leukemia and primary CNS lymphoma. To date, the capacity of a positive GRR in newly diagnosed NHL patients to predict CNS relapse has not been addressed. We retrospectively studied the prognostic value of GRR in cerebrospinal fluid samples of 148 newly diagnosed patients with high grade NHL. We demonstrate that positive GRR at diagnosis does not affect PFS or OS and did not predict CNS relapse. However, although numbers were small, repeated positive samples (≥ 2) correlated with a higher risk for CNS relapse (p = 0.048), possibly stressing the need for an aggressive preventive approach. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
33. Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse.
- Author
-
Goldschmidt, Neta, Horowitz, Netanel A., Heffes, Vered, Darawshy, Fares, Mashiach, Tatiana, Shaulov, Adir, Gatt, Moshe E., and Dann, Eldad J.
- Subjects
- *
DIFFUSE large B-cell lymphomas , *CENTRAL nervous system , *THERAPEUTICS , *METHOTREXATE , *RITUXIMAB , *PROGRESSION-free survival , *LYMPHOMAS , *VINCRISTINE - Abstract
Combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) is regarded as standard care for diffuse large B-cell lymphoma (DLBCL) and upfront intensification of therapy is still controversial. The current study aimed to dertermine whether the addition of high-dose methotrexate (HDMTX) affects long-term outcomes and could also prevent central nervous system (CNS) relapse. Medical records of 480 patients with DLBCL treated between 1994 and 2013 at Rambam and Hadassah medical centers in Israel were reviewed; 130 (27%) had received HDMTX. Patients receiving HDMTX generally had higher International Prognostic Index (IPI) and CNS-IPI scores. HDMTX addition significantly improved progression free and overall survival (p =.001) and this advantage was maintained in multivariate analysis (HR for OS 0.3; 95% CI 0.19–0.47; p <.0001). Thirty-one (6.5%) patients had CNS relapse and in these cases high CNS-IPI, but not HDMTX treatment, was independently associated with CNS relapse (HR 1.2; 95% CI 1.2–11.5; p =.02). In conclusion, the addition of HDMTX to CHOP/RCHOP independently and significantly improved prognosis of patients with high-risk DLBCL, irrespective of their risk for CNS relapse. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
34. Romidepsin-Bendamustine Combination for Relapsed/Refractory T Cell Lymphoma.
- Author
-
Nachmias, Boaz, Shaulov, Adir, Lavie, David, Goldschmidt, Neta, Gural, Alexander, Saban, Revital, Lebel, Eyal, and Gatt, Moshe E.
- Abstract
Background: The treatment of relapsed/refractory (R/R) peripheral T cell lymphoma (PTCL) is limited to a few agents. Romidepsin, a histone deacetylase inhibitor, was approved for PTCL treatment as a single agent in the R/R setting, yet with partial efficacy. Several attempts to combine romidepsin with other chemotherapy regimens have been reported, however, with significant toxicity. Objectives: To study the romidepsin-bendamustine combination in PTCL in an attempt to maximize efficacy while minimizing toxicity. Methods: We report on a series of 7 heavily pretreated PTCL patients (2–5 previous lines of therapy) treated with a romidepsin-bendamustine combination. Results: Four patients were not previously exposed to either drug. Of these, 2 achieved complete remission. Interestingly, 1 patient continued treatment with a prolonged progression-free survival of more than 4 years. Toxicity was minimal and no treatment-related deaths or discontinuation were noted. Significant nausea and vomiting were reported in over 50% of patients. Hematological toxicity was mild and lower than that reported for other romidepsin-chemotherapy combinations and was correlated with bone marrow involvement by lymphoma. Conclusions: Although reporting a small number of patients, our data suggest that the combination of romidepsin and bendamustine may be a feasible therapeutic option in R/R PTCL patients and merits further study. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
35. Daratumumab resistance is frequent in advanced‐stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis.
- Author
-
Pick, Marjorie, Vainstein, Vladimir, Goldschmidt, Neta, Lavie, David, Libster, Diana, Gural, Alexander, Grisariu, Sigal, Avni, Batia, Ben Yehuda, Dina, and Gatt, Moshe E.
- Subjects
- *
MULTIPLE myeloma , *CD38 antigen , *AMYLOIDOSIS , *MULTIPLE myeloma treatment , *FLOW cytometry , *DRUG administration , *DARATUMUMAB - Abstract
Abstract: Objective: Daratumumab is a promising new antimyeloma agent. We report a single center “real‐world” series of multiple myeloma (MM) and amyloidosis (AL) patients treated with daratumumab. Methods: Forty‐one patients were included: 7 second‐line MM, 30 heavily pretreated (median number of therapies of 5) advanced MM, and 4 with AL. Results: Second‐line patients and advanced AL showed high rate of durable overall responses. However, advanced MM patients had a dismal prognosis with an overall response rate (ORR) of 36%, and a short median progression‐free and overall survival of 2.3 and 6.6 months, respectively. Responses were particularly poor in patients with extramedullary plasmacytomas. Neither the addition of another agent to daratumumab nor changing to the next line of therapy produced significant durable responses in this patient population. Flow cytometry analysis demonstrated that CD38 expression level was not predictive of response. We show that CD38 expression dynamics by a commercially available anti‐CD38 antibody after daratumumab administration was hindered by competitive binding of daratumumab. Conclusions: Responses to daratumumab and combinations in patients with advanced MM, particularly with extramedullary disease, are low and short‐lived, stressing the administration of this agent should be early in the course of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
36. Primary plasma cell leukemia in the era of novel agents for myeloma – a multicenter retrospective analysis of outcome.
- Author
-
Ganzel, Chezi, Rouvio, Ory, Avivi, Irit, Magen, Hila, Jarchowsky, Osnat, Herzog, Katrin, Cohen, Yossi, Tadmor, Tamar, Horwitz, Netanel A., Leiba, Merav, Nagler, Arnon, Cohen, Yael, Bulvik, Shlomo, Polliack, Aaron, Rowe, Jacob M., and Gatt, Moshe E.
- Subjects
- *
PLASMA cell leukemia , *MYELOMA proteins , *MULTIPLE myeloma , *PROGNOSIS , *PROTEASOME inhibitors , *CELL transplantation , *CANCER chemotherapy - Abstract
Primary plasma cell leukemia (PPCL) is a rare form of multiple myeloma with a dismal prognosis. This retrospective multi-center study examines the national experience of PPCL in the era of novel agents. During 2002–2016, thirty-nine patients with PPCL were identified in 11 Israeli centers. One-fifth of them died in the first 2 months after diagnosis. The overall survival (OS) of those who survived the first 3 months was 22.5 months. About 70% of patients received at least one type of immunomodulatory drug (IMiD) and similarly proteasome inhibitor (PI) during treatment. There was a survival advantage for those who received IMiD but not for those who received PI or other type of standard dose chemotherapy. In multivariate analysis, low performance status and increased uric acid were also associated with shorter OS. In conclusion, this study demonstrates favorable impact of treatment with IMiDs and hematopoietic cell transplantation on the survival of PPCL patients. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
37. Gastrointestinal perforation in light chain amyloidosis in the era of novel agent therapy - a case series and review of the literature.
- Author
-
Shaulov, Adir, Avivi, Irit, Cohen, Yael, Duek, Adrian, Leiba, Merav, and Gatt, Moshe E.
- Subjects
- *
GASTROINTESTINAL diseases , *GASTROINTESTINAL disease treatment , *AMYLOIDOSIS , *PROGNOSIS , *SURGERY , *PATIENTS - Abstract
Gastrointestinal (GI) perforation is remarkably rare in patients with light chain (AL) amyloidosis and has not yet been reported in patients with AL amyloidosis treated with novel agents. Only 24 cases of GI perforation have previously been reported in the setting of AL amyloidosis of which 15 had available information in English. All 15 did not receive novel agent therapy and six died early after experiencing GI perforation. This study reports the characteristics and outcome of AL patients that developed GI perforation in the era of novel agent treatment. Seven patients were reviewed. In two patients, GI perforation was the presenting symptom of AL amyloidosis, whereas five patients developed GI perforations following initiation of an anti-AL therapy (three after bortezomib-based, 1 after lenalidomide-based and 1 after thalidomide-based therapy). All patients underwent surgery and survived the perforation. Treatment was renewed following surgery in six of seven patients, with no further GI complications. In conclusion, GI perforation in AL amyloidosis is rare and mostly reported after treatment initiation. Urgent surgery appears to be lifesaving and renewal of the anti-AL novel therapy appears to be safe, with no significant risk for re-perforation or GI toxicity. Prognosis in these patients is related to severity of the disease and response to therapy rather than the development of GI perforation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
38. The prognostic value of bone marrow involvement at the molecular level in aggressive lymphoma.
- Author
-
Goldschmidt, Neta, Darawshy, Fares, Kleinstern, Geffen, Slyusarevsky, Elena, Pogrebijski, Galina, Krichevsky, Svetlana, Ben-Yehuda, Dina, and Gatt, Moshe E.
- Subjects
- *
B cell lymphoma , *DIFFUSE large B-cell lymphomas , *LYMPHOMA diagnosis , *T cells , *HISTOPATHOLOGY , *TUMORS ,BONE marrow cancer - Abstract
We retrospectively studied the prognostic role of molecular (gene rearrangement, GRR) bone marrow (BM) involvement in diffuse large B-cell lymphoma (DLBCL, 424 patients) and in peripheral T-cell lymphoma (PTCL, 67 patients). When correlating BM GRR to histological findings at diagnosis, the GRR test was more sensitive (p = 0.036) but less specific (p < 0.0001) in PTCL than in DLBCL. For DLBCL (but not PTCL), a positive BM GRR correlated with advanced stage (p = 0.0001) and high IPI (p = 0.002), and worsened the progression free survival (PFS) (p = 0.05) and overall survival (OS) (p = 0.01), irrespective of rituximab treatment. Histologic negative/GRR positive cases had worse PFS/OS (p < 0.0001) than histologic/GRR double negative cases, however BM GRR was not an independent prognostic survival factor. End-of-treatment BM GRR did not predict survival. We conclude that BM GRR is unjustified as a prognostic tool for PTCL and should be reserved for a subset of DLBCL patients with negative histology of the BM. [ABSTRACT FROM PUBLISHER]
- Published
- 2017
- Full Text
- View/download PDF
39. Re-induction versus salvage for D14-resiudal acute myeloid leukemia: A retrospective multi-center study.
- Author
-
Frisch, Avraham, Aumann, Shlomzion, Zuckerman, Tsila, Leiba, Ronit, Gross Even-Zohar, Noa, Gatt, Moshe E., Vainstein, Vladimir, Shaulov, Adir, Gural, Alexander, Zimran, Eran, Zohar, Yaniv, Ofran, Yishai, and Nachmias, Boaz
- Subjects
- *
ACUTE myeloid leukemia , *DISEASE remission , *PURE red cell aplasia , *PROGNOSIS - Abstract
Remission assessment in acute myeloid leukemia has evolved over the recent years with the advent of molecular and flow-based minimal residual disease determination. Nonetheless, early time point such as day 5 and day 14 (D14), still have prognostic and therapeutic implications. D14 refractory disease is regarded as a poor prognostic factor, however the therapeutic intervention is still under debate, with evidence suggesting a successful re-induction might offer similar long-term outcome as D14 aplasia. Others advocate the use of more intensive salvage protocols as a mean to overcome the negative prognostic effect. In the current study, we compare outcome of D14 refractory AML patients treated with either re-induction or salvage protocol. More importantly, we identify response characteristics that might suggest which patients will benefit from re-induction approach. Accurate identification of chemotherapy refractory patients might allow the early incorporation of non-chemotherapy based protocols in the future. • Attaining CR after double induction was able to partly overcome the adverse prognosis of D14-residual disease. • A 50% blast decrease i at Day 14 is predictive for remission with 2nd cycle therapy and correlates with improved overall and event-free survival. • High dose cytarabine-based salvage regimen may benefit high-risk patients with D14-residual disease. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
40. Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy.
- Author
-
Goldschmidt, Neta, Kleinstern, Geffen, Orevi, Marina, Paltiel, Ora, Ben-Yehuda, Dina, Gural, Alex, Libster, Diana, Lavie, David, and Gatt, Moshe E
- Subjects
- *
B cell lymphoma , *HEALTH outcome assessment , *PRIMARY care , *RITUXIMAB , *TUMOR treatment ,MEDIASTINAL tumors - Abstract
Purpose: Outcomes in primary mediastinal B cell lymphoma (PMBL) improved with the introduction of dose intense treatments, consolidation radiotherapy and rituximab. DA-EPOCH-R, which omits radiotherapy has been adopted with worldwide enthusiasm, despite lack of proven superiority in randomized trials. We aimed to evaluate the course and outcome of PMBL using an alternative intensive rituximab-containing regimen, RCHOP-RICE. We also evaluated the prognostic value of (18)FDG-PET-CT (PET-CT).Methods: We reviewed the clinical, laboratory and imaging data of PMBL patients receiving 1st-line treatment in Hadassah Medical Center between 8/2002 and 10/2014.Results: Of 47 PMBL patients, 24 (51 %) were treated with RCHOP-RICE and 23 (49 %) with other protocols. Overall, the 5-year progression-free survival was 93 % and the overall survival was 98 % (87 and 100 %, respectively, for the RCHOP-RICE regimen). Patient characteristics and treatment toxicities were balanced among protocols. A mean of 11.1 ± 1.3 hospitalization days/patient were needed to administer RCHOP-RICE regimen compared to 37 ± 2 days/patient for DA-EPOCH-R (n = 2). Radiotherapy was given to 3 patients (12 %) treated with RCHOP-RICE compared to 18 patients (78 %) treated with other protocols (p < 0.01). For patients followed with interim and end of treatment (EOT) PET-CT, we observed a significant reduction in the uptake between the two (p < 0.0001). Using a Deauville score cutoff of 3, the negative and positive predictive values (NPV and PPV) of EOT PET-CT were 94 and 33 %, respectively.Conclusions: The RCHOP-RICE protocol results in excellent survival outcomes, generally permits omission of RT and is simpler to administer than DA-EPOCH-R. Interim PET-CT in PMBL may be unjustified; however, EOT Deauville scores ≤3 predicts a favorable outcome. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
41. Phase I/ II study exploring ImMucin, a pan-major histocompatibility complex, anti- MUC1 signal peptide vaccine, in multiple myeloma patients.
- Author
-
Carmon, Lior, Avivi, Irit, Kovjazin, Riva, Zuckerman, Tsila, Dray, Lillian, Gatt, Moshe E., Or, Reuven, and Shapira, Michael Y.
- Subjects
- *
MULTIPLE myeloma treatment , *CANCER vaccines , *PEPTIDE drugs , *MAJOR histocompatibility complex , *CELLULAR signal transduction , *CELLULAR immunity - Abstract
ImMucin, a 21-mer cancer vaccine encoding the signal peptide domain of the MUC1 tumour-associated antigen, possesses a high density of T- and B-cell epitopes but preserves MUC1 specificity. This phase I/ II study assessed the safety, immunity and clinical response to 6 or 12 bi-weekly intradermal ImMucin vaccines, co-administered with human granulocyte-macrophage colony-stimulating factor to 15 MUC1-positive multiple myeloma ( MM) patients, with residual or biochemically progressive disease following autologous stem cell transplantation. Vaccination was well tolerated; all adverse events were temporal grade 1 2 and spontaneously resolved. ImMucin vaccination induced a robust increase in γ-interferon ( IFN-γ-producing CD4+ and CD8+ T-cells (≤80-fold), a pronounced population of ImMucin multimer CD8+ T-cells (>2%), a 9·4-fold increase in peripheral blood mononuclear cells proliferation and 6·8-fold increase in anti-ImMucin antibodies, accompanied with T-cell and antibody-dependent cell-mediated cytotoxicity. A significant decrease in soluble MUC1 levels was observed in 9/10 patients. Stable disease or improvement, persisting for 17·5-41·3 months (ongoing) was achieved in 11/15 patients and appeared to be associated with low-intermediate PDL1 ( CD274) bone marrow levels pre- and post-vaccination. In summary, ImMucin, a highly tolerable cancerous vaccine, induces robust, diversified T- and B-cell ImMucin-specific immunity in MM patients, across major histocompatibility complex-barrier, resulting in at least disease stabilization in most patients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
42. Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia.
- Author
-
Vine, Jacob, Cohen, Sara Bar, Ruchlemer, Rosa, Goldschmidt, Neta, Levin, Moshe, Libster, Diana, Gural, Alexander, Gatt, Moshe E., Lavie, David, Ben-Yehuda, Dina, and Rund, Deborah
- Subjects
- *
CHRONIC myeloid leukemia , *GENETIC polymorphism research , *MULTIDRUG resistance , *CATIONS , *IMATINIB , *PROTEIN-tyrosine kinases , *PHARMACOGENOMICS , *HEALTH outcome assessment - Abstract
The optimal tyrosine kinase inhibitor for any individual patient with chronic myeloid leukemia (CML) is not predictable. Pharmacogenetic parameters and trough levels of imatinib (IM) have each been independently correlated with response. We therefore studied the human organic cation transporter (h OCT1) and multidrug resistance ( MDR1) single nucleotide polymorphisms (SNPs) and correlated these with IM levels and major molecular response (MMR) (3-log reduction) in 84 patients with CML, the first such study performed in Caucasians. We studied MDR1 G2677T and C3435T, and for h OCT1, C480G and A1222G. IM levels varied significantly with dose (< or > 400 mg/day) ( p = 0.038) and were significantly lower in 20 patients who lost MMR ( p = 0.042). Adjusting for dose, trough IM levels were not significantly correlated with SNPs. Patients with MDR1 3435 TT had significantly longer times to MMR compared to CC/CT genotypes ( p = 0.047). Genotypes did not predict treatment failure when controlling for IM levels. We conclude that IM levels, but not the SNPs studied here, determine IM failure. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
43. Increased risk of central venous catheter-associated thrombosis in acute promyelocytic leukemia: a single-institution experience.
- Author
-
Grisariu, Sigal, Spectre, Galia, Kalish, Yosef, and Gatt, Moshe E.
- Subjects
- *
ACUTE promyelocytic leukemia , *CENTRAL venous catheters , *THROMBOEMBOLISM , *ACUTE leukemia , *ACUTE myeloid leukemia , *PLATELET count , *HEPARIN , *CANCER chemotherapy , *PATIENTS - Abstract
Background Patients with acute leukemia and in particular, acute promyelocytic leukemia ( APL), are felt to be at high risk for developing venous thromboembolism. The presence of central venous catheters ( CVCs) increases this risk; however, reports have varied regarding the frequency of this complication. Current guidelines do not recommend the routine use of prophylactic anticoagulation for patients with CVC. Methods We suspected an increased incidence of CVC thrombosis in patients with APL and therefore conducted a retrospective survey of 473 patients who were treated for acute leukemia at our institution. Results The overall rate of symptomatic CVC thrombosis was 6.8%. We found a significantly ( P < 0.001) increased rate of symptomatic CVC thrombosis (32%) in patients with APL as compared with patients with acute lymphocytic leukemia and acute myeloid leukemia (6.4% and 4%, respectively). CVC thrombosis was most prevalent following induction treatment and was associated with higher platelet counts in patients with APL. Following this observation, 13 additional newly diagnosed patients with APL were treated with low molecular weight heparin prophylaxis during the recovery phase after chemotherapy. None had a thrombotic event. Conclusions Although our treatment group was small, we suggest considering prophylaxis for CVC thrombosis during platelet recovery after induction treatment in patients with APL. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
44. Prolonged Fever, Hepatosplenomegaly, and Pancytopenia in a 46-Year-Old Woman.
- Author
-
Levy, Liran, Nasereddin, Abedelmajeed, Rav-Acha, Moshe, Kedmi, Meirav, Rund, Deborah, and Gatt, Moshe E.
- Subjects
- *
PHAGOCYTOSIS , *BLOOD cells , *LIVER diseases , *SPLEEN diseases , *FEVER , *EDEMA , *DISEASES - Abstract
The article presents a case study of a 46-year-old woman who was hospitalized due to prolonged high-grade fever, night sweats and weight loss. Her diagnostic findings include enlarged liver and spleen, edema, pancytopenia and hemophagocytosis, and she was diagnosed with hemophagocytic syndrome. She underwent empiric treatment with high-dose immunoglobulin, dexamethasone and cyclosporin A, resulting to substantial improvement. Details on hemophagocytic lymphohistiocytosis (HLH) are also included.
- Published
- 2009
- Full Text
- View/download PDF
45. Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma.
- Author
-
Azoulay, David, Lavie, David, Horowitz, Netanel, Suriu, Celia, Gatt, Moshe E., Akria, Luiza, Perlman, Riki, Braester, Andrei, and Ben‐Yehuda, Dina
- Subjects
- *
MULTIPLE myeloma treatment , *BORTEZOMIB , *NEUROPATHY , *BRAIN-derived neurotrophic factor , *ALTERNATIVE medicine , *BLOOD platelets - Abstract
The article discusses a study that describes alterations of bortezomib-induced peripheral neuropathy (BIPN) in patients with multiple myeloma (MM). It shows that reduced soluble brain-derived neurotrophic factor (sBDNF) levels in the plasma concomitant with elevated BDNF content in platelets of MM patients that developed BIPN. It unveils that the patients who developed BIPN had undetectable subclinical disease-related neuropathy before starting treatment.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.